Overview

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Metformin